Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

Abstract Background Prospective evidence is lacking regarding incremental benefits of long-acting dual- versus mono-bronchodilation in improving symptoms and preventing short-term disease worsening/treatment failure in low exacerbation risk patients with chronic obstructive pulmonary disease (COPD)...

Full description

Bibliographic Details
Main Authors: François Maltais, Leif Bjermer, Edward M. Kerwin, Paul W. Jones, Michael L. Watkins, Lee Tombs, Ian P. Naya, Isabelle H. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri, Claus F. Vogelmeier
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Respiratory Research
Subjects:
COPD
Lung function
Dyspnoea
Clinically important deterioration
Bronchodilator therapy
Online Access:http://link.springer.com/article/10.1186/s12931-019-1193-9

Internet

http://link.springer.com/article/10.1186/s12931-019-1193-9

Similar Items